In 2023, Alexander Hardy earned $1.99M in total compensation at BioMarin Pharmaceuticals, including $1.05M salary and $900.00K bonus. Most recently acquired 88,720 shares in Mar 2025. Currently holds stock worth $8.45M. 2+ years at the helm of BioMarin Pharmaceuticals.
Compensation History
Annual executive compensation data for Alexander Hardy, including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$1.99M
Salary
$1.05M
Bonus
$900.00K
Other
$40.22K
Salary
$1.05MBoard Justification
The compensation philosophy aims to attract and retain executive talent necessary to advance the business and increase stockholder value, with a strong emphasis on performance-based compensation.
Bonus
$900.00KBoard Justification
Signing bonus as a 'make whole' component for potential forfeited bonus at his prior employer due to the timing of the transition late in the year.
Other Compensation
$40.22KBoard Justification
Includes reimbursement of legal expenses in connection with the review of his employment agreement and imputed income associated with life insurance premium payments.
Restricted Stock
Board Justification
No stock was vested in 2023 as Mr. Hardy was appointed CEO effective December 1, 2023, and did not receive any performance-based equity awards for 2023.
Performance Metrics
Performance metrics for 2023 were not applicable to Mr. Hardy as he was appointed CEO on December 1, 2023.
Alexander Hardy
CEO of BioMarin Pharmaceuticals
Education
B.A. from the University of Cambridge; M.B.A. from the University of Michigan’s Ross School of Business
Field of Expertise
Healthcare & Life Sciences - Biotechnology
Sector of Economy
Healthcare
CEO of BioMarin Pharmaceuticals for
2 years 0 months (Dec 2023 - Present)
Previous Experience
Chief Executive Officer of Genentech, Inc.; Head of Global Product Strategy at Roche; various leadership roles at Genentech and Novartis.
Other BioMarin Pharmaceuticals CEOs
Holdings
Track Alexander Hardy's stock holdings and portfolio value over time.
Insider Trading
Alexander Hardy's recent stock transactions, purchases, and sales filed with the SEC.
88,720 shares
BMRN
Mar 14, 2025
Received
$16.80K
BMRN at $56.01/share
Nov 29, 2024
Received
32,780 shares
BMRN
Mar 15, 2024
Received
115,371 shares
BMRN
Dec 1, 2023
Received
Rivals
Compare Alexander Hardy with competitor CEOs and industry peers.